Pfizer PFE announced that it is discontinuing the development of danuglipron, its investigational oral GLP-1 receptor agonist (GLP-1 RA), which is being developed to treat obesity. The decision ...

Key Takeaways A pill to treat obesity caused liver injury in a clinical trialPfizer said it will stop developing the drug, called danuglipron, as a result Other alternatives to injectable obesity ...

Medications like Ozempic, Wegovy, and Zepbound have helped many Americans lose weight, but there are still some misconceptions about these medications and metabolic health. Centre Spring MD founder ...

People who have tried other methods to lose weight have found results from obesity drugs that ‘feel like magic.’ ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing.

Mounjaro's launch of a weight-loss drug has sparked interest amongst the people of India despite the high price. Experts believe that making the drug locally available would help to reduce the black ...

Mounjaro, a once-weekly injection approved by India's drug regulator, is priced at 4,375 rupees ($50.86) for a 5 milligram ...